Related Blog Posts from the Wikinvest Wire

ArQule (ARQL)   Subscribe to ArQule (ARQL) content from the Wikinvest Wire
 » Back to ArQule (NASDAQ:ARQL) Stock Page


1/16/13(ARQL) ArQule Shares Fall on Oncology Drug Candidate Setback (Stock Blog Hub)

ArQule Inc. (ARQL) and partner Daiichi Sankyo recently announced disappointing phase II results on oncology candidate, tivantinib (ARQ 197). The study evaluated ArQule’s lead pipeline candidate, tivantinib, in combination with Pfizer’s (PFE) Camptosar (irinotecan) and Bristol-Myers Squibbs/Eli Lilly’s (BMY/LLY) Erbiutx (cetuximab) in patients with refractory or relapsed colorectal cancer (CRC). The study failed to meet its [...]

1/18/12(ARQL) Company News for January 18, 2012 – Corporate Summary (Stock Blog Hub)

•    Bio technology company ArQule Inc.’s (NASDAQ:ARQL) share prices gained 11.91% to close at $6.67 after the company's experimental treatment for liver cancer reported a positive outcome in its Phase II trial •    Share prices of discount carrier Sprint Airlines Inc. (NASDAQ:SAVE) declined 5.53% after the company announced plans to sell 11 million shares in a [...]

10/11/10ArQule and Daiichi Sankyo Reach Agreement with FDA (Benzinga)

ArQule, Inc. (Nasdaq: ARQL) today announced a Special Protocol Assessment agreement with the U.S. Food and Drug Administration for the design of a Phase 3 trial of ARQ 197 in patients with non-small cell lung cancer of non-squamous histology. Daiichi Sankyo Co., Ltd., the holder of the Investigational New Drug application for ARQ 197 and ArQule's partner for the development of the compound, will conduct the Phase 3 trial, which is planned for initiation later this year.

3/31/10Trading results 3/31/10 (Robert Weinstein Trading Blog)

Good end to a good month Today started out with ARQL and I traded it a few times today. I started out long at the open then went short where I made the bulk of the gains and then went short in small size a couple more times including near the end of the day. [...]

Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki